Cure My Disease

Don't miss your cure!

 Log in / Sign up

Wearable patch aims to catch hidden heart rhythms that holter monitors miss

NCT ID NCT07722026

Diagnosis Sponsor: HUINNO Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial tests whether a wearable patch called MEMO Patch V2 can detect heart rhythm disorders (arrhythmias) more effectively than the standard 24-hour Holter monitor. Adults with symptoms like palpitations or dizziness, or those who have had a stroke of unknown cause, will wear the patch for up to 14 days while also undergoing a 24-hour Holter recording. The study compares how often each device catches an arrhythmia and checks the patch's signal quality, comfort, and skin safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a wearable patch-type ECG monitor called MEMO Patch V2
What this could lead to
If the patch proves more effective, it could offer a more convenient and longer-lasting way to catch intermittent heart rhythm problems that a 24-hour monitor might miss.
What could go wrong
This is a small pilot study, so results may not be definitive. The patch may cause skin irritation or be less comfortable to wear for 14 days, and longer monitoring could pick up harmless irregularities that lead to unnecessary worry.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

150 people

The number who actually took part.

Started

Sep 2021

Finished

Jul 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 19 to 80 years. 2. Participants who required ECG monitoring because of suspected arrhythmia associated with symptoms such as palpitations or dizziness; or participants with cryptogenic ischemic stroke or transient ischemic attack. 3. Participants able to wear MEMO Patch V2 for 14 days. 4. Participants who received a detailed explanation of the study, fully understood it, and voluntarily provided written informed consent. Exclusion Criteria: 1. History of allergic reactions to adhesive products. 2. Participants who required inpatient management during the study because of atrial fibrillation, stroke, transient ischemic attack, another clinically significant condition as determined by the investigator, or a history of dehydration or syncope within 1 year before screening. 3. Any other condition that, in the investigator's judgment, made the participant unsuitable for study participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cryptogenic ischemic stroke are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac cardiac rhythm disease Dizziness ischemic stroke transient ischemic attack

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cryptogenic ischemic stroke Dizziness Palpitations Suspected arrhythmia Transient ischemic attack

Contacts and locations

Locations

  • Korea University Anam Hospital

    Seoul, 02841, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.